Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid

Iranian Journal of Kidney Diseases

Volumn 3, Issue 3, 2009, Pages 141-144

  Shojaei, Mir Hatef ^a   Djalali, Mamhmoud ^a   Siassi, Fereydoun ^a   Khatami, Mohammad Reza ^b   Boroumand, Mohammad Ali ^b   Eshragian, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Homocysteine; Hydroxymethylglutaryl CoA reductase inhibitors; Lipoprotein(a)

Indexed keywords

ATORVASTATIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PYRIDOXINE; HEPTANOIC ACID DERIVATIVE; LIPOPROTEIN A; PYRROLE DERIVATIVE; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; EATING; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; EATING; FEMALE; FOLIC ACID; HEPTANOIC ACIDS; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); LOVASTATIN; MALE; MIDDLE AGED; PYRROLES; RENAL DIALYSIS; RISK FACTORS; VITAMIN B 6; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 70349912682     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dierkes J, Luley C, Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag. 2007;3:99-108.
2. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261-7.
3. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol. 1993;33:574-80.
4. Ikizler TA. Protein and energy intake in advanced chronic kidney disease: how much is too much? Semin Dial. 2007;20:5-11.
5. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother. 2008;42:9-15.
6. Kaisar M, Isbel N, Johnson DW. Cardiovascular disease in patients with chronic kidney disease. A clinical review. Minerva Urol Nefrol. 2007;59:281-97.
7. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005;16:1794-802.
8. Navarro JF, Mora C, Muros M, Garcia-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract. 2003;95:c128-35.
9. Righetti M. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med. 2007;45:1586-9.
10. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007;38:1959-66.
11. Sunder-Plassmann G, Winkelmayer WC, Fodinger M. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 2000;9:2637-51.
12. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;4:143-50.
13. Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. 2008;28:254-64.
14. Food and Nutrition Board: Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academies Press; 2002.
15. Yilmaz FM, Yilmaz G, Duranay M, et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scand J Clin Lab Invest. 2005;65:739-45.
16. Tsai YH, Park S, Snook JT. Interaction among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified diets. J Nutr Biochem. 1998;9:106-13.
17. Nestel P, Noakes M, Belling B, et al. Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet. J Lipid Res. 1992;33:1029-36.
18. Mensink RP, Zock PL, Katan MB, Hornstra G. Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J Lipid Res. 1992;33:1493-501.
19. Monte G, Mezdour H. [The pharmacological effects of certain compounds on lipoprotein(a)]. Recenti Prog Med. 1993;84:855-63. Italian.
20. Heinz J, Domrose U, Westphal S, Luley C, Neumann KH, Dierkes J. Washout of water-soluble vitamins and of homocysteine during haemodialysis: effect of high-flux and low-flux dialyser membranes. Nephrology (Carlton). 2008;13:384-9.
21. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl. 2001;78:S234-7.